Twenty-one patients with relapsed or refractory germ cell tumors were treated with high-dose chemotherapy and marrow transplantation (HDC/BMT) from 1982-1993. Primary sites of disease were testis (17), ovary (three), and pineal gland (one). Pathology included dysgerminoma (one), choriocarcinoma with adenocarcinoma (one), seminoma (four), and nonseminoma or mixed germ cell tumor (15). Nineteen had at least two prior chemotherapy regimens and eight had cisplatinrefractory disease defined as progression within 4 weeks of a cycle of cisplatin-based chemotherapy. HDC regimens were mostly combinations of cyclophosphamide with etoposide and cisplatin or carboplatin. There were only two treatment-related deaths (aspergillosis and interstitial pneumonitis). Times to engraftment of granulocytes (21 ± 8.3 days) and platelets (32 ± 20.2 days) were reasonable with only the last nine patients receiving growth factors. At a minimum of 4 years follow-up, eight patients have died of disease, six of whom were cisplatin-refractory prior to transplant. Eleven patients (52% overall) are alive and continuously free of disease after 4-10 years including one of three with refractory ovarian germ cell tumor. HDC/BMT provides significant long-term disease-free survival as salvage therapy for both male and female relapsed germ cell tumor patients who are not refractory to cisplatin. Keywords: germ cell tumors; bone marrow transplantation; relapsed; cisplatin-refractory Metastatic germ cell tumors in both male and female patients are potentially curable with cisplatin-based combination chemotherapy with or without additional surgery.
ily pretreated patients with disseminated germ cell tumors from four large centers in the USA and Europe have been analyzed retrospectively for prognostic variables that predict a poor outcome with high-dose chemotherapy and hematopoietic stem cell support. 10 The resulting model categorized patients into three groups based on the number of prognostic factors present and allows the separation of poor (3-5 risk factors) risk patients from good (0 risk factors) and intermediate (1 or 2 risk factors) risk patients who might still have a beneficial outcome (27-51% 2-year failure-free survival) following high-dose chemotherapy and autologous stem cell support. Female patients with ovarian germ cell neoplasms were excluded from this analysis and although published data on high-dose chemotherapy with stem cell support for ovarian germ cell tumors is relatively scarce, there are reports 6 that suggest the utility of this approach in this population with germ cell malignancies as well. We retrospectively reviewed our own experience of high-dose chemotherapy with autologous marrow transplant for refractory or relapsed germ cell tumors in both men and women and analyzed survival data in patients with a minimum of 4 years follow-up.
Patients and methods

Data collection
During an 11-year period from September 1982 to September 1993, records of 293 consecutive autologous hematopoietic stem cell transplants performed at the University of Oklahoma Health Sciences Center were screened by diagnosis. Twenty-two of these were bone marrow transplants performed for 21 patients with a diagnosis of germ cell neoplasm and were selected for this report. Among the 21 patients, three were women who had refractory ovarian germ cell tumors. One male patient had an extragonadal primary embryonal carcinoma of the pineal gland whereas the rest had primary testicular cancers.
Definitions
A single prior chemotherapy regimen consisted of at least two and up to four cycles of similar agents used successively. Tumor stage was classified for most patients based on the Indiana classification system of minimal, moderate and advanced disease. 11 Tumor markers represented either beta-HCG or alpha fetoprotein or both. For response cri-teria, the definitions used by Beyer et al 10 were used: clinical complete remission (cCR), total radiographic disappearance of measurable tumor and normalization of tumor markers with chemotherapy alone; pathologic complete remission (pCR), complete resection of no viable malignancy (necrosis or fibrosis) or mature teratoma without any evidence of residual tumor; surgical complete remission (sCR), complete resection of viable malignancy or immature teratoma without any evidence of residual tumor; marker-negative partial remission (PRm−), greater than 50% reduction of radiologically measurable disease with normal tumor markers; marker-positive partial remission (PRm+) greater than 50% reduction of radiologically measurable disease with elevated tumor markers, or greater than 90% reduction of elevated tumor markers; progressive disease (PD), an increase of any radiologically measurable tumor by greater than 25% or a greater than 10% increase of elevated tumor markers; stable disease (SD), represented a response that did not qualify as either PRm− or PRm+ or a PD. Response assessments were performed 4-6 weeks after the transplant date. Clinically meaningful responses consisted of cCR, pCR, sCR and PRm−. Cisplatin-refractoriness was defined for disease that showed progression (radiologically or by rising tumor markers) within 4 weeks of the last cycle (of at least two cycles) of cisplatin-based standard-dose chemotherapy.
Pre-transplant evaluation
All patients undergoing autologous marrow transplantation underwent pre-transplant screening and satisfied the following criteria prior to transplant: Southwest Oncology Group (SWOG) performance status of 0-2; age less than 60 years; marrow biopsy and aspirate free of tumor by morphologic criteria; hemoglobin Ͼ10 g/dl; white cell count Ͼ4.5 x 10 9 /l; platelet count Ͼ135 x 10 9 /l; technically accessible posterior iliac crest marrow; serum creatinine Ͻ2.0 mg/dl or creatinine clearance Ͼ60 cc/min; no evidence of severe pulmonary insufficiency; no clinical evidence of cardiac decompensation, serious arrhythmias or recent myocardial infarction; total bilirubin Ͻ3 mg/dl.
Marrow harvest, storage and reinfusion
Bone marrow was obtained under general anesthesia by a multiple aspiration technique from both posterior iliac crests. 12 Between 1000-1500 ml was procured to reach total nucleated cell number that exceeded 1 x 10 8 cells/kg body weight. Following procurement, marrow cells were processed as previously described to yield a single cell suspension. 13 Nucleated cells were concentrated by centrifugation to obtain a volume of 100-200 ml for freezing. Cryopreservation was carried out using 10% dimethyl sulfoxide as the cryopreservative and a programmed freezing rate of 1°C per min to −40°C with rapid override of the heat of fusion. Frozen marrow was then stored in metal canisters in the vapor phase of liquid nitrogen (−150°C). For reinfusion, cryopreserved marrow was rapidly thawed in a 37°C water bath. The bags (containing approximately 100 ml) were individually thawed and infused within 15 min to avoid undue cell clumping.
General patient management and supportive care
Marrow procurement was done in the outpatient setting or on the first day of admission for the transplant procedure. Patients were housed in single intensive-care rooms without benefit of specialized air handling (HEPA filtration of laminar airflow systems). Double-or triple-lumen tunneled central venous catheters were utilized for vascular access. Standard mask and hand-washing isolation was carried out when granulocyte counts were less than 0.5 x 10 9 /l. Antibiotic prophylaxis was started early for gut decontamination and discontinued when empiric i.v. antibiotics were started for neutropenic fevers. All antibiotics were continued until resolution of signs of infection and granulocyte counts rose to more than 0.5 x 10 9 /l for 3 consecutive days (engraftment).
Antiviral and antifungal agents were employed according to clinical circumstances and prevailing common practices of the transplant community. Platelets and other blood component support were administered as clinically indicated. Growth factor support following marrow infusion was used only in the last nine patients beginning in 1991.
Statistical analysis
Survival analysis was performed using Kaplan-Meier method with a microcomputer running the statistical package JMP version 3.1.6.2 from the SAS Institute Inc.
14 Overall survival time was calculated from the day of marrow reinfusion until the date of death or last news. Patients known to be alive were censored at the time of last news irrespective of disease status. Event-free survival (EFS) was calculated from the day of marrow infusion until the date of treatment failure (disease progression, relapse, or death whichever occurred first). Patients without a treatment failure were also censored at the time of last news. The log-rank test was used to compare survival times. Table 1 presents a summary of clinical characteristics and pathology of 21 patients with germ cell tumors included in this report. The median age was 24 years with a range of 16-57 years. Seventeen had the testis as the primary site at diagnosis (10 nonseminoma, four seminoma, three mixed). One male with normal ultrasound of the testes had disseminated disease with a mass in the pineal gland that showed an embryonal carcinoma on biopsy. Three women had ovarian primaries (one choriocarcinoma with adenocarcinoma component, one dysgerminoma and one embryonal carcinoma). Two patients received prior cranial irradiation (one for primary tumor and the other for metastatic nonseminoma) in addition to combination chemotherapy. Two others also had prior abdominal irradiation (to the retroperitoneum) either as initial therapy for a stage II seminoma or as adjunctive therapy following combination chemotherapy for embryonal carcinoma. Prior chemotherapy details on the first patient were unavailable whereas 571 the rest either had cisplatin/vinblastine/bleomycin (eight patients), cisplatin/etoposide/bleomycin (nine patients), or cisplatin/etoposide (three patients) as first-line combination chemotherapy. Subsequent chemotherapy for relapsing or refractory disease consisted mostly of cisplatin/ifosfamide with either vinblastine or etoposide. Ninety percent (19) had at least two chemotherapy regimens prior to transplantation and 43% (nine) had at least three. Just prior to transplant, two were in complete remission, 11 in partial remission regardless of marker status, and eight had refractory disease with either rising markers or progressive new lesions.
Results
Patient characteristics and pathology
Transplantation-related data and toxicity
Preparative regimens used for dose-intensive therapy varied according to the time period patients were admitted for transplantation ( Table 2 ). All received high-dose cyclophosphamide and all except one were also administered a platinum compound (cisplatin or carboplatin). Twothirds of the patients were given a more consistent protocol that included carboplatin (1600-2000 mg/m 2 ), cyclophosphamide (120 mg/kg) and etoposide (1200-2400 mg/m All evaluable patients engrafted within the usual range for autologous bone marrow as the source of stem cells (see Table 2 ). Growth factors were given only for the last nine patients and consisted mostly of either filgrastim (5 g/kg) or sargramostim (250 g/m 2 ) begun 7 days after marrow infusion.
Non-hematologic toxicity grading based on common toxicity criteria is listed in Table 3 . About 25% of patients developed grade 3-4 toxicity mostly either infection or peripheral neuropathy or hearing loss which tended to get better with time. Two died of treatment-related causes: one from disseminated aspergillosis 20 days from marrow infusion and the other of diffuse interstitial pneumonitis 23 days from transplant. Both were heavily pretreated with three or more prior chemotherapy regimens with or without radiation. At autopsy both still had viable tumor at their respective sites of disease (embryonal carcinoma in retroperitoneal nodes and in pineal gland). IU class at diag = Indiana University staging classification at time diagnosis; Unk = unknown; Min = minimal; Mod = moderate; Adv = advanced; Nonsemin = nonseminomatous elements not specified or combination of embryonal carcinoma, teratocarcinoma, yolk sac, choriocarcinoma; TeratoCa = teratocarcinoma; Dysgermin = dysgerminoma; Mixed = combination of seminoma and nonseminomatous elements; Chorio = choriocarcinoma; Adeno = adenocarcinoma; Prior treatment regimen = aXRT = abdominal irradiation; cXRT = cranial irradiation; Surg = surgery; A = Adriamycin; B = Bleomycin; C = Cyclophosphamide; Cb = Carboplatin; E or V = Etoposide; HM = high-dose methotrexate; I = Ifosfamide; P = Cisplatin; Ve = Vinblastine; rel = relapse; RPN = retroperitoneal nodes; Med = mediastinum; ␤HCG = beta human chorionic gonadotropin (mIU/ml); ␣FP = alpha feto-protein(ng/ml); nl = normal; TD = toxic death; +Ca = viable cancer; RPLND = retroperitoneal lymph node dissection; mo = months from transplant; DOD = dead of disease; NED = no evidence of disease. See text for response definitions.
Responses and survival
resection of a liver lesion following a PRm− response to transplant was performed in one patient with no viable carcinoma seen thus converting him to a pCR (pathologic CR). The three other PRm− responders refused or failed to show up for post-transplant surgery and eventually opted for close observation. Two patients with a PRm+ response to one transplant underwent attempts at surgical resection showing viable carcinoma; one died of disease at 5 months; the other obtained only a short PRm− response (2 months) with a second transplant but survived for 18 months before dying from his disease as well. Three other patients with PRm+ best responses relapsed within 2-7 months and survived only 5-18 months after transplant. One patient who had progression of disease despite transplant died 3 months later. Among the patients who had meaningful responses, three relapsed at 3-5 months post-transplant with survivals of 8-20 months; the rest (11 patients, 52% overall) are alive and free from relapse 4-10 years out. Kaplan-Meier eventfree and overall survival plots are shown in Figure 1 . 
Cisplatin-refractoriness and long-term survival outcome
Retrospectively, patients could be grouped as having disease that has shown refractoriness to chemotherapy at any time vs patients whose disease remained responsive to chemotherapy subsequent to relapse or as second-line salvage for incomplete or slow responses to first-line treatment. Twelve (12/21, 57%) patients could be categorized as having chemoresponsive disease and nine (43%) as having chemorefractory disease. Eight out of nine chemorefractory disease patients were deemed refractory to cisplatin at any point in their chemotherapy history (one during first-line and seven during subsequent chemotherapy). Refractoriness to cisplatin-based therapy could not be assessed in one patient due to incomplete data. Four out of these eight (50%) cisplatin-refractory patients never showed a meaningful response to transplant and all four eventually died of germ cell cancer. One cisplatin-refractory patient suffered a toxic death although he still had viable carcinoma at autopsy. Four others obtained either a PRm− or cCR but only one of these patients is alive and disease-free. This particular patient was a 17-year-old female who had a large right ovarian embryonal carcinoma with peritoneal metastases treated initially with excision of the right ovary then chemotherapy with bleomycin, etoposide and cisplatin. She progressed with new pulmonary and hepatic lesions shortly after five cycles of this regimen. After salvage chemotherapy with adriamycin/ifosfamide then carboplatin and etoposide, she was taken to transplant obtaining a PRm−. Six years later, she remains well and has given birth to a healthy child. Figure 2 shows survival curves of cisplatin-refractory patients vs those who had never shown any refractoriness to a cisplatin-containing regimen. Even with small numbers, this difference is significant with a log-rank test P value of 0.0082. The median survival for patients who are not cisplatin-refractory has not been reached with an overall survival curve plateauing at better than 75% at a minimum of 4 years follow-up. 
Discussion
Salvage conventional-dose chemotherapy for relapsing or refractory germ cell tumors is able to cure 20-25% of patients with or without additional surgery. 3 Early experience of high-dose chemotherapy with autologous marrow or stem cell support (HDC/SCT) in multiply relapsed or refractory patients has shown that 10-15% could be saved with this approach. [4] [5] [6] [7] [8] [9] We have summarized the results of our experience of high-dose chemotherapy with autologous marrow transplantation for less heavily pre-treated patients with relapsed or refractory germ cell malignancies in both men and women. This small series of patients suffering from a relatively uncommon disease illustrates that up to 52% of relapsed or refractory patients could still obtain long-term event-free survival of more than 4 years.
Our numbers are too small to perform multivariate analyses of different prognostic factors or an analysis of univariate factors for subgroups. A collaborative effort from four larger centers in Europe and the USA, 10 however, has generated a prognostic model based on five pre-transplant prognostic factors that can predict outcome following transplantation for relapsed and refractory germ cell tumors in males. The five factors included progressive disease before HDC, mediastinal primary tumor, refractory disease before HDC, absolute refractory disease, and beta-HCG Ͼ1000 U/l before HDC. Three risk categories were made based on the number of factors: good (score 0) with a failure-free survival (FFS) of 51% at 2 years; intermediate (score [1] [2] with an FFS of 27%; and poor (score Ͼ2) with an FFS of only 5%. The population of 238 patients on which this prognostic model was based included many heavily pretreated patients entered in the initial transplant studies who failed to respond to a cisplatin-based first-line regimen and at least one conventional-dose salvage regimen (mean of 87%). In our series, about 38% (8/21, refractory) failed to respond to a salvage regimen just prior to undergoing HDC. The rest either had a PR (11) or a CR (two) going into transplantation. This could certainly partly explain the relatively higher overall 3-year survival outcome of 52 vs 30% in the international report. 10 Various investigators [15] [16] [17] [18] [19] [20] have published their results utilizing HDC/SCT in less heavily pre-treated patients or as part of an early salvage strategy for poor risk candidates with germ cell tumors (incomplete response or inappropriate tumor marker decline to first-line chemotherapy, or treatment in first relapse with or without induction chemotherapy). Table 5 summarizes pertinent information of these results including the current report. Event-free survivals vary for each study from 34 to 67%. Variations in the patient population may account for differing results. The Table divides the studies based on the number of patients in each study reported to have extragonadal primaries, a prognostic factor known to have a poor outcome for response. 21, 22 Several observations may be made from the results described in Table 5 . In group A or the three studies that reported 33-45% incidence of extragonadal primaries in their patient pool (A1-A3: Refs 15-18), one or two cycles of HDC (of a two or three-drug regimen) resulted in a 34-45% EFS. The incidence of cisplatin-refractoriness could 574 NA = not applicable; NM = not mentioned; ND = not determinable; cyc = cycle; Chemotherapy regimen: VAB-6 = vinblastine, dactinomycin, cyclophosphamide, bleomycin, cisplatin; HIPE = weekly cisplatin, etoposide, vincristine; B = bleomycin; Cb = carboplatin; Cy = cyclophosphamide; E or V = etoposide; I or Ifx = Ifosfamide; P = cisplatin; Th = thiotepa; Ve = vinblastine.
only be ascertained in the Rodenhuis 17 study (33%) for this group since in the other two studies 15, 16, 18 most relapsed patients did not receive induction chemotherapy just prior to transplant or were transplanted early for incomplete responses to initial therapy. In group B or the three studies that included a 5% or less incidence of patients with extragonadal primaries (B4-B6: Refs 19, 20 and this study), one cycle of HDC resulted in a 39-67% long-term EFS. The study by Broun 19 which reported a relatively lower 39% EFS did not mention the number of cisplatin-refractory patients and used only a two-drug HDC regimen of carboplatin/etoposide. The two other studies in group B (B5 B6) which quoted a 67 and 52% EFS had a 33 and 38% incidence respectively, of cisplatin-refractory patients but used a three-drug HDC regimen of carboplatin/etoposide plus either ifosfamide or cyclophosphamide. Motzer and Bosl 23, 24 have suggested that the incorporation of an oxazophosphorine (cyclophosphamide or ifosfamide) to carboplatin/etoposide in the high-dose regimen may result in a higher proportion of complete and durable responses. Indeed, two (40%) out of five patients who did not proceed to transplant in the Broun 21 study for various other reasons, obtained long-term remissions with conventional ifosfamide plus cisplatin-based salvage therapy. Two patients in the Motzer 23 study who had persistent elevation of tumor markers after one round of carboplatin/etoposide HDC were converted to CR and are long-term disease-free survivors after four additional post-transplant courses of conventional-dose VIP, 16 an ifosfamide/cisplatin-based regimen. The addition of ifosfamide or cyclophosphamide to a carboplatin/etoposide HDC regimen may certainly be important especially if only a single round of HDC is planned. However, a clear advantage in terms of higher rate of response or survival benefit could not be demonstrated for a particular high-dose chemotherapy regimen used in the international collaborative study, 10 which included combinations of carboplatin/etoposide (one or two transplants), and carboplatin/etoposide/cyclophosphamide or ifosfamide.
Selecting which particular group of patients may benefit the most from HDC/SCT is important in being able to utilize this approach more efficiently and also in attempting to develop more innovative treatment designs for those who may not. In our series, cisplatin-refractoriness defined as disease progression within 4 weeks of a cycle of cisplatinbased chemotherapy regimen, predicted for a poor longterm outcome with transplantation (12% durable remission). Patients who were still responsive to induction chemotherapy obtained the most benefit with a 77% eventfree survival at 4 years ( Figure 2 , log-rank test, P value 0.0082). Using tandem HDC with ifosfamide/ carboplatin/etoposide and marrow transplantation, Lotz et al 22 showed only an 18% (5/28) long-term disease-free survival (10-84 months) in 28 germ cell tumor patients (18 testis, seven extragonadal, three ovarian) who were all refractory to cisplatin. Other investigators have also indicated the importance of cisplatin-refractoriness as a prognostic factor. 10, 25, 26 The process of administration of induction chemotherapy for relapsing patients could certainly select out the cisplatin-sensitive population that may benefit from HDC. Transplanting patients in untreated relapse (without benefit of induction chemotherapy and testing for cisplatin-refractoriness) even with two cycles of HDC did not seem to offer an overall advantage in one study (see Table 5 , Margolin: 1/7, 14% EFS). 18 Patients in this study who have remained progressionfree at 2 years are likely to be cured of their germ cell tumors. Many patients in this series are able to live highly productive lives with minor morbidity (peripheral numbness, some hearing loss). The one female survivor in this report delivered a normal healthy child 6 years after her transplant. It is now almost 7 years after and she is doing well free from relapse.
High-dose chemotherapy with autologous marrow or stem cell transplantation clearly has a role in salvage therapy of both male and female patients with germ cell tumors. Relapsing or incompletely responding patients who have not shown cisplatin-refractory disease may benefit the most especially if they maintain marker-negative responses to conventional salvage induction regimens. Those who have cisplatin-refractory disease can expect only a 10-20% chance of durable remission with this approach.
